camrelizumab； famitinib malate + platinum-based chemotherapy
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
Jul 23, 2021 → May 31, 2027
NCT ID
NCT04906993About camrelizumab； famitinib malate + platinum-based chemotherapy
camrelizumab； famitinib malate + platinum-based chemotherapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Cervical Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04906993. Target conditions include Cervical Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04906993 | Phase 3 | Active |
Competing Products
20 competing products in Cervical Cancer